JPH0479890A - Recovery and purification of pyrroloquinolinequinones - Google Patents
Recovery and purification of pyrroloquinolinequinonesInfo
- Publication number
- JPH0479890A JPH0479890A JP19392990A JP19392990A JPH0479890A JP H0479890 A JPH0479890 A JP H0479890A JP 19392990 A JP19392990 A JP 19392990A JP 19392990 A JP19392990 A JP 19392990A JP H0479890 A JPH0479890 A JP H0479890A
- Authority
- JP
- Japan
- Prior art keywords
- pqq
- culture
- culture solution
- pqqs
- impurities
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011084 recovery Methods 0.000 title description 5
- 238000000746 purification Methods 0.000 title description 2
- ATTTYDOGGQCDDK-UHFFFAOYSA-N C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 Chemical class C1=CC2=CC(=O)C(=O)NC2=C2C=CN=C21 ATTTYDOGGQCDDK-UHFFFAOYSA-N 0.000 title 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims abstract description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- 239000012535 impurity Substances 0.000 claims abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 239000012228 culture supernatant Substances 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 3
- ADXCEOBGDCQCKM-UHFFFAOYSA-N quinoline-2,3-dione Chemical class C1=CC=CC2=NC(=O)C(=O)C=C21 ADXCEOBGDCQCKM-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000006228 supernatant Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940111121 antirheumatic drug quinolines Drugs 0.000 abstract 2
- 150000003248 quinolines Chemical class 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 241000862974 Hyphomicrobium Species 0.000 description 4
- 241000589323 Methylobacterium Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 241000589210 Acidomonas methanolica Species 0.000 description 1
- 241000862972 Ancylobacter Species 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 229930189936 Glyoxalase Natural products 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000589321 Methylobacillus glycogenes Species 0.000 description 1
- 241001535042 Methylobacterium mesophilicum Species 0.000 description 1
- 241000122248 Methylophaga Species 0.000 description 1
- 241000191760 Methylophaga marina Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000605118 Thiobacillus Species 0.000 description 1
- 241000589494 Xanthobacter autotrophicus Species 0.000 description 1
- 241000589495 Xanthobacter flavus Species 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- -1 inorganic acid salts Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、ピロロキノリンキノン類の製造法に関し、さ
らに詳細には、細菌を使用して生成させたピロロキノリ
ンキノン類の回収・精製方法に係わる。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to a method for producing pyrroloquinoline quinones, and more particularly to a method for recovering and purifying pyrroloquinoline quinones produced using bacteria. Involved.
ピロロキノリンキノン類(以下 PQQ類と記す)は、
細菌に限らず、真核生物のカビおよび酵母、さらには哺
乳動物などの組織中にも存在し、脱水素酵素および酸化
酵素のそれぞれの補酵素として重要な働きを担っている
。さらに近年までに細胞の増殖促進作用(たとえば特開
昭61−58584号公報、特開昭63−233783
号公報)、アルドース還元酵素阻害作用−抗白内障作用
(たとえば特開昭63−41421号公報、特開昭63
−48215号公報、特開昭6429313号公報)、
肝臓疾患予防治療作用(たとえば特開昭63−1927
17号公報)、創傷治癒作用(たとえば特開昭63−1
52309号公報)、抗アレルギー作用(たとえば特開
昭63−174931号公報)、逆転写酵素阻害作用(
たとえば特開昭63−156724号公報、特開平01
−29313号公報)およびグリオキサラーゼ■阻害作
用−制癌作用(たとえば特開昭63−215628号公
報、特開平01−239313号公報)など多くの生理
活性が明らかにされている。また、ビタミン作用を有す
ることも明らかとなっており、医薬品として重要な役割
を果たす物質と考えられている。Pyrroloquinoline quinones (hereinafter referred to as PQQs) are:
It is present not only in bacteria but also in the tissues of eukaryotic molds and yeasts, as well as mammals, and plays an important role as a coenzyme for dehydrogenases and oxidases. Furthermore, in recent years, cell proliferation promoting effects (for example, JP-A No. 61-58584, JP-A No. 63-233783)
(Japanese Patent Application Laid-Open No. 63-41421, Japanese Patent Application Laid-open No. 63-41421,
-48215 Publication, Japanese Patent Application Laid-Open No. 1988-6429313),
Preventive and therapeutic effects on liver diseases (e.g. JP-A-63-1927)
No. 17), wound healing effect (for example, JP-A-63-1
52309), anti-allergic action (for example, JP-A-63-174931), reverse transcriptase inhibitory action (
For example, JP-A-63-156724, JP-A-01
Many physiological activities have been revealed, including glyoxalase (1) inhibitory action and anticancer action (for example, JP-A-63-215628 and JP-A-01-239313). It has also been shown that it has a vitamin effect, and is considered to be a substance that plays an important role as a medicine.
〔従来の技術、発明が解決しようとする問題点〕従来、
PQQ類を含有する培養液からPQQ類を回収・精製す
る方法としては、培養液から細菌菌体を遠心分離などの
方法により除去した培養上澄液をDEAE−3epha
dex (ジエチルアミノエチル系陰イオン交換樹脂
−セファデックス−A25ファルマシア社、商品名)カ
ラムを通過させて、このカラムにPQQ類を吸着させた
後、0〜IM KCI溶液でPQQ類を溶出する方法
(M、 Ameyama et al、、 Agric
Biol、 Chem、、 第48巻、第561頁〜
565頁(1984)が知られている。[Prior art, problems to be solved by the invention] Conventionally,
As a method for recovering and purifying PQQs from a culture solution containing PQQs, bacterial cells are removed from the culture solution by a method such as centrifugation, and the culture supernatant is purified using DEAE-3epha.
A method of passing through a dex (diethylaminoethyl anion exchange resin - Sephadex - A25 Pharmacia, trade name) column to adsorb PQQs on this column, and then eluting the PQQs with a 0 to IM KCI solution ( M., Ameyama et al., Agric
Biol, Chem, Volume 48, Page 561~
565 pages (1984) is known.
しかしながら、この方法では、培養上澄液中に含まれて
いる蛋白質などの不純物のために得られるPQQ類の純
度が低く、また純度の高いPQQ類を得るためには、多
量のDEAE−3ephadex樹脂を必要とするなど
の問題があり、培養液からPQQ以外の有機物の有効な
除去方法の開発が望まれている。However, with this method, the purity of the PQQs obtained is low due to impurities such as proteins contained in the culture supernatant, and in order to obtain PQQs with high purity, a large amount of DEAE-3 ephadex resin is required. Therefore, there is a need to develop an effective method for removing organic substances other than PQQ from the culture solution.
本発明者らは、培養液からのPQQ類の回収・精製方法
について、研究を重ねた結果、培養液または培養液から
細菌菌体を全部あるいは一部除去した培養上澄液のpH
を3.0〜4.5にすることにより培養液あるいは培養
上澄液中に含まれる蛋白質などの不純物が沈澱となり、
これを遠心分離あるいは濾過などの方法で除去すること
により蛋白質などの不純物が取り除け、PQQ類の回収
・精製が容易に行なえることを見出し、本発明を完成し
た。As a result of repeated research on methods for recovering and purifying PQQs from culture fluids, the present inventors found that the pH of culture fluids or culture supernatants from which all or part of the bacterial cells have been removed is
By setting the value to 3.0 to 4.5, impurities such as proteins contained in the culture solution or culture supernatant become precipitates.
The present invention has been completed based on the discovery that impurities such as proteins can be removed by removing this by centrifugation or filtration, making it easy to recover and purify PQQs.
すなわち、本発明は、メタノール資化性を有し、かつ、
ピロロキノリンキノンを生産する能力を有する細菌を用
いてピロロキノリンキノン類を製造する方法において、
メタノールを主炭素源として含有する培地で当該細菌を
増殖させピロロキノリンキノン類を生成させた培養液、
または培養液から細菌菌体を全部あるいは一部除去した
培養上澄液のpHを3.0〜4,5とし、不純物を除去
することを特徴とするピロロキノリンキノン類の回収・
精製方法である。That is, the present invention has methanol assimilation ability, and
In a method for producing pyrroloquinoline quinones using bacteria capable of producing pyrroloquinoline quinone,
A culture solution in which the bacteria are grown in a medium containing methanol as a main carbon source to produce pyrroloquinoline quinones,
Alternatively, the collection of pyrroloquinoline quinones is characterized by removing all or part of the bacterial cells from the culture solution, adjusting the pH of the culture supernatant to 3.0 to 4.5, and removing impurities.
This is a purification method.
本発明におけるPQQ類とは、PQQ 、 PQQのナ
トリウム塩およびPQQのカリウム塩などのPQQ塩類
を意味する。PQQ in the present invention means PQQ salts such as PQQ, sodium salt of PQQ, and potassium salt of PQQ.
メタノール資化性を有し、かつ、PQQを生産する能力
を有する細菌としては、たとえば、メチロバチルス・グ
リコゲネス、メチロバクテリウムエクストロクエンス、
メチロバクテリウム オルガノフィラム、メチロバクテ
リウム ロブイウム、メチロバクテリウム メソフィリ
カム、メチロバクテリウム ラジオトレランス、ハイホ
ミクロビウム プルガレ、ハイホミクロビウム メチロ
ボラム、アンシロバクター アキュアティカス、キサン
トバクタ−オートトロフィカス、キサントバクタ−フラ
バス、アシドモナス メタノリカ、パラコツカス デニ
トリフィカンス、バラコツカス アルカリフィラス、チ
オバチルス ノベルス、メチロファーガ マリーナおよ
びメチロフアーガ サラシカなどがあり、これらの細菌
を、メタノールを炭素源とする培地中で培養して得られ
た培養液には、PQQの他に比較的多量の蛋白質などの
有機物からなる不純物を含有している。Examples of bacteria that have the ability to assimilate methanol and produce PQQ include Methylobacillus glycogenes, Methylobacterium extroquens,
Methylobacterium organophyllum, Methylobacterium robium, Methylobacterium mesophilicum, Methylobacterium radiotolerance, Hyphomicrobium pulgare, Hyphomicrobium methyloborum, Ancylobacter acuaticus, Xanthobacter autotrophicus , Xanthobacter flavus, Acidomonas methanolica, Paracotcus denitrificans, Baracotcus alkalinephyllus, Thiobacillus novelus, Methylophaga marina, and Methylophaga salicica, and these bacteria can be cultured in a medium using methanol as a carbon source. In addition to PQQ, the culture solution contains a relatively large amount of impurities consisting of organic substances such as proteins.
細菌菌体を含む培養液そのもののpHを3.0〜4゜5
にすることにより、含有している蛋白質などの不純物は
、細菌菌体と共に沈澱するので、遠心分離あるいは濾過
などの手段により除去でき、細菌菌体および蛋白質など
の不純物のないPQQ含有液を得ることができる。しか
し、細菌菌体を含む培養液そのものを使用すると沈澱物
が多量となるためにPQQ類も沈澱物にまき込まれ、P
QQの回収率が低下するなどの問題がある。そこで細菌
菌体の全部あるいは一部をあらかじめ除去した培養上澄
液を得、そのpHを3.0〜4.5とし、蛋白質などの
不純物を除去することが特に好ましい。The pH of the culture solution itself containing bacterial cells is 3.0-4°5.
By doing so, impurities such as contained proteins will precipitate together with the bacterial cells, so they can be removed by means such as centrifugation or filtration, and a PQQ-containing liquid free of impurities such as bacterial cells and proteins can be obtained. I can do it. However, if the culture solution containing bacterial cells itself is used, a large amount of precipitate will be produced, and PQQs will also be mixed into the precipitate.
There are problems such as a decline in the QQ collection rate. Therefore, it is particularly preferable to obtain a culture supernatant from which all or part of the bacterial cells have been removed in advance, adjust its pH to 3.0 to 4.5, and remove impurities such as proteins.
培養液あるいは培養上澄液中のPQQ類の濃度には、特
に制限はないが、PQQ類の濃度が高いとPQQ類の回
収率が低くなることから、1g/Il以下が好ましく、
特に800mg/V以下が好ましい。PQQ類をこれら
より多く含有する培養液あるいは培養上澄液を用いる場
合には、PQQ類の濃度が、これらの値以下となるよう
に水を添加する必要がある。The concentration of PQQs in the culture solution or culture supernatant is not particularly limited, but if the concentration of PQQs is high, the recovery rate of PQQs will be low, so it is preferably 1 g/Il or less,
Particularly preferred is 800 mg/V or less. When using a culture solution or culture supernatant containing PQQs in a larger amount than these values, it is necessary to add water so that the concentration of PQQs is below these values.
また逆に、PQQ濃度がこれらの値以下の場合には、濃
縮処理などを行ってもよい。Conversely, if the PQQ concentration is below these values, concentration processing or the like may be performed.
培養上澄液のpHが4.5を越えると、蛋白質の除去量
が少なくなり、また、一方pH3,0未満であると、蛋
白質の除去率はよいものの、PQQの回収率が悪(なる
。そこで培養上澄液のpHは3.0〜4.5の間で行わ
れる。蛋白質の除去率およびPQQの回収率から、特に
pH3,5〜4.0が好ましい。If the pH of the culture supernatant exceeds 4.5, the amount of protein removed will decrease, while if the pH is less than 3.0, the protein removal rate will be good, but the PQQ recovery rate will be poor. Therefore, the pH of the culture supernatant is set between 3.0 and 4.5.From the viewpoint of protein removal rate and PQQ recovery rate, pH 3.5 to 4.0 is particularly preferred.
培養液あるいは培養上澄液のpHを3.0〜4.5とす
るために、塩酸および硫酸などの酸類ならびに重炭酸ナ
トリウムあるいは酸性リン酸カルシウムなどの無機酸性
塩などの酸性物質が添加されるがこれらの中では酸類が
好ましく塩酸が特に好ましい。In order to adjust the pH of the culture solution or culture supernatant to 3.0 to 4.5, acidic substances such as acids such as hydrochloric acid and sulfuric acid and inorganic acid salts such as sodium bicarbonate or acidic calcium phosphate are added. Among these, acids are preferred, and hydrochloric acid is particularly preferred.
本発明により得られたPQQ含有液を、DEAR−3e
phadexカラム処理、5ephadex G−10
カラム処理、ハイポーラスポリマーカラム処理(特願昭
62−232296 ) 、塩析処理(特願昭63−2
16317 >などの精製を行うことにより容易に純度
のよいPQQ類を回収率よく得ることが可能である。The PQQ-containing liquid obtained according to the present invention was applied to DEAR-3e
phadex column treatment, 5ephadex G-10
Column treatment, high porous polymer column treatment (Japanese patent application No. 62-232296), salting-out treatment (Japanese patent application No. 63-2
16317>, etc., it is possible to easily obtain PQQs with good purity at a high recovery rate.
以下、実施例によって本発明をさらに具体的に説明する
。Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例 l
ハイホミクロビウム メチロボラム DSM 186
9(Urakami and komagata、 J
、 Gen、 Appl、 Microbiol、、第
33巻、第521頁〜第542頁、(1987))を培
養して得られた培養液を遠心分離して、菌体を除去し、
PQQを含有する培養上澄液を得た。この培養上澄液は
PQQを約600μg/m/、蛋白質を約2g/l含有
していた。Example l Hyphomicrobium methyloborum DSM 186
9 (Urakami and Komagata, J.
, Gen, Appl, Microbiol, Vol. 33, pp. 521-542, (1987)), the resulting culture solution was centrifuged to remove bacterial cells,
A culture supernatant containing PQQ was obtained. This culture supernatant contained about 600 μg/m of PQQ and about 2 g/l of protein.
この培養上澄液を100m1づつ10群に分け、各々の
pHを6.0〜1.5になるように塩酸を添加して調整
した。調整4時間後に12.000rpmで20分間遠
心分離し、沈澱物を除去し、その上澄液中のPQQ濃度
および蛋白質濃度を分析した。PQQは高速液体クロマ
トグラフィーで分析し、蛋白質はLowry法で分析し
た。結果を表1に示す。This culture supernatant was divided into 10 groups of 100 ml each, and the pH of each group was adjusted to 6.0 to 1.5 by adding hydrochloric acid. After 4 hours of adjustment, the mixture was centrifuged at 12,000 rpm for 20 minutes to remove the precipitate, and the PQQ concentration and protein concentration in the supernatant were analyzed. PQQ was analyzed by high performance liquid chromatography, and protein was analyzed by the Lowry method. The results are shown in Table 1.
第
表
実施例 2
ハイホミクロビウム メチロボラム DSM 1869
を培養して得られた培養液を遠心分離して、菌体を除去
し、PQQを含有する培養上澄液を得た。この培養上澄
液は、PQQを433μg/l、蛋白質を1、350g
g#’含有していた。Table Example 2 Hyphomicrobium Methyloborum DSM 1869
The culture solution obtained by culturing was centrifuged to remove the bacterial cells and obtain a culture supernatant containing PQQ. This culture supernatant contained 433 μg/l of PQQ and 1.350 g of protein.
g#' was contained.
この培養上澄液21に、HCIを添加し、pHを3゜5
に調整した。調整4時間後に12. OOOrpmで2
0分間遠心分離し、沈澱物を除去し、PQQ含有液を得
た。このPQQ含有液には、PQQを348μg/l、
蛋白質を38μg/l含有していたに
のPQQ含有液に120gのNaClを添加し溶解後、
HCIを添加しpHを2.5に調整し、5℃で24時間
放置後、12.00Orpmで20分間遠心分離し沈澱
物を得た。この沈澱物を凍結乾燥し、PQQ含有粉体を
1、42g得た。この粉体はPQQ・2Naを697m
g 、 NaC1を587mg 、蛋白質を9mg 、
水を114mg 、その他13mgを含有していた。HCI was added to this culture supernatant 21 to adjust the pH to 3.5.
Adjusted to. 12. After 4 hours of adjustment. OOOrpm 2
The mixture was centrifuged for 0 minutes, the precipitate was removed, and a PQQ-containing solution was obtained. This PQQ-containing solution contained 348 μg/l of PQQ,
After adding 120 g of NaCl to the PQQ-containing solution containing 38 μg/l of protein and dissolving it,
HCI was added to adjust the pH to 2.5, and after standing at 5°C for 24 hours, centrifugation was performed at 12.00 rpm for 20 minutes to obtain a precipitate. This precipitate was freeze-dried to obtain 1.42 g of PQQ-containing powder. This powder contains 697m of PQQ・2Na.
g, 587 mg of NaCl, 9 mg of protein,
It contained 114 mg of water and 13 mg of other substances.
比較例 l
実施例2において得られたPQQを433μg/l、蛋
白質を1.350gg/V含有している培養上澄液21
に、120gのNaC1を添加し溶解後、HCIを添加
しpHを2.5に調整し、5°Cで24時間放置後、1
2. OOOrpmで20分間遠心分離し沈澱物を得た
。Comparative Example 1 Culture supernatant 21 containing 433 μg/l of PQQ and 1.350 gg/V of protein obtained in Example 2
After adding 120g of NaCl and dissolving it, HCI was added to adjust the pH to 2.5, and after leaving it at 5°C for 24 hours,
2. The mixture was centrifuged at OOOrpm for 20 minutes to obtain a precipitate.
この沈澱物を凍結乾燥し、PQQ含有粉体を4.27g
得た。この粉体はPQQ ・2Naを750mg 、
NaC1を700mg、蛋白質を2.5g、水を220
mg 、その他100 mgを含有していた。This precipitate was freeze-dried to obtain 4.27 g of PQQ-containing powder.
Obtained. This powder contains 750 mg of PQQ 2Na,
700mg of NaCl, 2.5g of protein, 220g of water
mg, and 100 mg of others.
本発明により、PQQの回収・精製が容易に行うことが
可能となり、工業的に極めて大きな利点がある。The present invention makes it possible to easily recover and purify PQQ, which has an extremely large industrial advantage.
Claims (1)
を生産する能力を有する細菌を用いてピロロキノリンキ
ノン類を製造する方法において、メタノールを主炭素源
として含有する培地で当該細菌を増殖させ、ピロロキノ
リンキノン類を生成させた培養液、または、培養液から
細菌菌体を全部あるいは一部除去した培養上澄液のpH
を、3.0〜4.5とし、不純物を除去することを特徴
とするピロロキノリンキノン類の回収・精製方法。In a method for producing pyrroloquinoline quinones using bacteria that have the ability to assimilate methanol and produce pyrroloquinoline quinone, the bacteria are grown in a medium containing methanol as the main carbon source, pH of the culture solution that produced quinoline quinones or the culture supernatant after removing all or part of the bacterial cells from the culture solution
3.0 to 4.5 and removing impurities.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19392990A JP3036009B2 (en) | 1990-07-24 | 1990-07-24 | Method for recovering and purifying pyrroloquinoline quinones |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19392990A JP3036009B2 (en) | 1990-07-24 | 1990-07-24 | Method for recovering and purifying pyrroloquinoline quinones |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0479890A true JPH0479890A (en) | 1992-03-13 |
JP3036009B2 JP3036009B2 (en) | 2000-04-24 |
Family
ID=16316094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP19392990A Expired - Lifetime JP3036009B2 (en) | 1990-07-24 | 1990-07-24 | Method for recovering and purifying pyrroloquinoline quinones |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3036009B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012082165A (en) * | 2010-10-12 | 2012-04-26 | Chemo-Sero-Therapeutic Research Inst | New adjuvant |
CN104892597A (en) * | 2015-05-14 | 2015-09-09 | 郑州轻工业学院 | Complex extraction method for separation and purification of pyrroloquinoline quinine in fermentation broth |
-
1990
- 1990-07-24 JP JP19392990A patent/JP3036009B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012082165A (en) * | 2010-10-12 | 2012-04-26 | Chemo-Sero-Therapeutic Research Inst | New adjuvant |
CN104892597A (en) * | 2015-05-14 | 2015-09-09 | 郑州轻工业学院 | Complex extraction method for separation and purification of pyrroloquinoline quinine in fermentation broth |
CN104892597B (en) * | 2015-05-14 | 2016-05-04 | 郑州轻工业学院 | PQQ in complexing abstraction separation and purification zymotic fluid |
Also Published As
Publication number | Publication date |
---|---|
JP3036009B2 (en) | 2000-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3542601B2 (en) | Protein separation | |
KR20070081458A (en) | A method for collecting vitamin k2 | |
JPH0231689A (en) | Purification of pertussis toxin | |
JPS5944320A (en) | Preparation of c1 inactivating agent | |
JPS6344883A (en) | Novel hyaluronidase sd-678 and production thereof | |
JPH0479890A (en) | Recovery and purification of pyrroloquinolinequinones | |
JPH0834742B2 (en) | Pertussis endotoxin removal method, pertussis toxoid and its manufacturing method | |
JP2692167B2 (en) | Method for recovering and purifying pyrroloquinoline quinones | |
CA1274250A (en) | Purification and recovery of phenylalanine with calcium salts | |
JPH03294281A (en) | Method for producing oxazopyrroloquinolines | |
JPH07113024B2 (en) | Method for purifying pyrroloquinoline quinone | |
JP3737252B2 (en) | Method for recovering and purifying protein having epidermal growth factor activity | |
JPS61275224A (en) | Collagenase-inhibiting agent | |
JP2002255988A5 (en) | ||
JP2006325538A (en) | Method for producing bacillus natto kinase and the resultant bacillus natto kinase | |
WO1982002834A1 (en) | Process for recovering interferon | |
JP2011030485A (en) | Method for producing pyrroloquinolinequinones by using metal ion | |
JPS6031479B2 (en) | Method for producing pure chondroitinase C | |
JPH08176199A (en) | Method for purifying hirudine by affinity chromatography | |
US20020015711A1 (en) | Purification of a pertussis outer membrane protein | |
JPS6120268B2 (en) | ||
JP4383822B2 (en) | Cancer cell distant metastasis inhibitor | |
JP3025067B2 (en) | Method for producing glyoxalase I | |
CN112194658A (en) | Separation and purification method of pyrroloquinoline quinone | |
JP2537074B2 (en) | Purification method of acid protease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080225 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090225 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100225 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110225 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110225 Year of fee payment: 11 |